Barclays »

Rapport Therapeutics shares owned by Barclays

Quarter-by-quarter ownership of Rapport Therapeutics (RAPP) shares owned by Barclays from 13F filings

Historical chart of Barclays investment in Rapport Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Rapport Therapeutics held by Barclays consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Rapport Therapeutics by Barclays

Quarter filed Position value Share count Share price at filing
2024-09-30 $264k 13k 20.52
2024-06-30 $219k 9.4k 23.30

More positions owned by Barclays

SPDR S&ampP 500 ETF TR Fund (SPY)
Invesco Qqq Tr Opt Put Option (QQQ)
Microsoft Corp Opt Call Option (MSFT)
Ishares Tr Opt Call Option (IWM)
Apple Opt Put Option (AAPL)
NVIDIA Corporation (NVDA)
Amazon (AMZN)
Alphabet Inc Class A cs (GOOGL)
Tesla Opt Put Option (TSLA)
Ishares Tr Fund (HYG)
Facebook Inc cl a (META)
Berkshire Hathaway (BRK.B)
Broadcom (AVGO)
Visa (V)
Alphabet Opt Put Option (GOOG)

View all positions for Barclays

Top funds holding Rapport Therapeutics

Arch Venture Corp
Cormorant Asset Management
Capital Research and Management Company - Division 3
Johnson & Johnson
Sofinnova Ventures
T. Rowe Price Investment Management
Alliancebernstein
T. Rowe Price Associates
Perceptive Advisors
BlackRock
Citadel Advisors
Siren
Logos Global Management
Geode Capital Management
Woodline Partners

View all funds holding Rapport Therapeutics